Heart failure (HF) is a growing health problem. Despite improved management and outcome, the number of patients with HF is expected to keep rising in the following years. In recent research, adiponectin was shown to exert beneficial effects in the cardiovascular system, but the protein was also implicated in the development and progression of HF. The objective of this review is to provide an overview of current knowledge on the role of adiponectin in HF with reduced ejection fraction. We discuss the cardioprotective and (anti-) inflammatory actions of adiponectin and its potential use in clinical diagnosis and prognosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10741-016-9578-z | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!